Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

benign neonatal seizures (BFNS) - Clinical Profile, Treatments & Trials | Kisho | Kisho

Rare Disease

benign neonatal seizures

MONDO:0016027

Also known as:BFNSbenign familal neonatal seizuresbenign familial convulsion

Overview

A rare genetic epilepsy syndrome characterized by the occurrence of afebrile seizures in otherwise healthy newborns with onset in the first few days of life.

Treatments1 FDA approved

Clinical Presentation

Built from Human Phenotype Ontology (HPO) phenotype annotations and GeneReviews clinical descriptions. Features represent findings documented across known cases — not an exhaustive list of possible symptoms.

No HPO annotations are available for this condition.

GeneReviews

Clinical Guidance

KCNQ2-related disorders include a continuum of overlapping neonatal-onset epileptic phenotypes ranging from self-limited familial neonatal epilepsy (SLFNE) at the mild end to neonatal-onset developmental and epileptic encephalopathy (NEO-DEE) at the severe end. Less common phenotypes consist of neonatal encephalopathy with non-epileptic myoclonus, later-onset (infantile or childhood) developmental and epileptic encephalopathy (DEE), and isolated intellectual disability (ID) without epilepsy. KCNQ2 variants have also been associated with peripheral nerve hyperexcitability (myokymia), self-limited familial infantile epilepsy (SLFIE), or self-limited familial neonatal-infantile epilepsy (SLFNIE) in a small number of families or individuals.

Diagnosis

Drawn from GeneReviews diagnostic guidelines, newborn screening panel status (RUSP), and ClinGen gene-disease validity classifications. Reflects current clinical evidence and consensus where available.

GeneReviews

Diagnostic Criteria

KCNQ2-related disorders represent a continuum of overlapping neonatal epileptic phenotypes ranging from self-limited familial neonatal epilepsy (SLFNE) at the mild end to neonatal-onset developmental and epileptic encephalopathy (NEO-DEE) at the severe end. Individuals with pathogenic variants in KCNQ2 with other phenotypes including neonatal encephalopathy with non-epileptic myoclonus, epilepsy developing in infancy or childhood, and isolated intellectual disability (ID) without epilepsy have also been described.

Suggestive Findings

A KCNQ2-related disorder should be considered in individuals with the following presentations.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

1 FDA-approved treatment is available for benign neonatal seizures, including PHENOBARBITAL SODIUM (SEZABY, approved 2022). An additional 2 compounds hold orphan drug designation.

Approved Therapies

Brand Name	Generic Name	Mechanism	Approved	Market Status

Prognosis

Based on GeneReviews surveillance recommendations, HPO phenotype frequency and severity annotations, and published prevalence estimates from Orphanet and OMIM.

GeneReviews

Surveillance Guidelines

Table 5.

Recommended Surveillance for Individuals with a KCNQ2-Related Disorder

System/Concern | Evaluation | Frequency

Neurologic

| Monitor w/EEG. | KCNQ2-SLFNE:

At age 3, 12, 24 mos

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

No clinical trials have been registered for benign neonatal seizures.

62 publications have been identified in PubMed for benign neonatal seizures. Research spans Case Report / Case Series (29%), Basic Science / Preclinical (23%), and Epidemiology / Natural History (21%).

Research Type	Count	% of Total
Patient case studies	18	29%

Data assembled from 5 of 12 sources · Last updated Sep 20, 2026, 1:03 AM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

External Resources

Orphanet

European rare disease database

Orphanet:1949

GARD

Genetic and Rare Diseases Info Center

GARD:1519

Questions for Your Care Team

→What are the benefits and potential side effects of SEZABY for managing benign neonatal seizures?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

GeneReviews

Differential Diagnosis

Genetic disorders in the differential diagnosis of KCNQ2-related epilepsy. No specific EEG trait characterizes a KCNQ2-related disorder. The genetic differential diagnosis of KCNQ2-related epilepsy includes the differential diagnoses for: • Self-limited familial neonatal epilepsy (SLFNE); • Self-limited familial infantile epilepsy (SLFIE); • Self-limited familial neonatal-infantile epilepsy (SLFNIE); and • Developmental and epileptic encephalopathy (DEE). Table 2. Selected Genes To Consider in the Differential Diagnosis of KCNQ2-Related Epilepsy

Gene(s)	Epilepsy Phenotype	MOI	Clinical Features of DiffDx Disorder
KCNQ3	Self-limited familial neonatal epilepsy (SLFNE)	AD	KCNQ2-SLFNE KCNQ3-SLFNE are clinically indistinguishable; thus, molecular genetic testing of both genes is commonly performed when SLFNE is suspected. PRRT2 SCN2A
SCN8A	Self-limited familial infantile epilepsy (SLFIE) self-limited familial neonatal-infantile epilepsy (SLFNIE) (OMIM PS601764)	AD	SLFIE SLFNIE can closely resemble SLFNE in rare instances. In SLFIE, seizure onset is nearly always by age ~6 mos. In SLFNIE, age of seizure onset can vary w/in a family incl both neonatal infantile onset.1
100 genes; more commonly involved genes:ARXSCN2ASCN8ASTXBP1	Neonatal-onset developmental epileptic encephalopathy (NEO-DEE) (OMIM PS308350)	XLAD2	When seizure onset is w/in the 1st few days of term birth, KCNQ2 is the most commonly involved gene; when seizures begin later in the neonatal period, the chance that another gene is involved .3 No other clinical features or EEG findings discriminating among these candidates are known.

Source: GeneReviews — "KCNQ2-Related Disorders"

GeneReviews

Management Guidelines

No clinical practice guidelines for KCNQ2-related disorders have been published. Evaluations Following Initial Diagnosis To establish the extent of disease and needs in an individual diagnosed with a KCNQ2-related disorder, the evaluations summarized (if not performed as part of the evaluation that led to diagnosis) are recommended. Table 3. Recommended Evaluations Following Initial Diagnosis in Individuals with a KCNQ2-Related Disorder

System/Concern	Evaluation	Comment
Neurologic	Neurologic eval	To incl brain MRI EEG; Video EEG monitoring incl sleep phase to obtain information on presence of seizures. A burst-suppression EEG pattern might only be seen during sleep.
Development	Developmental assessment	To incl motor, adaptive, cognitive, speech/language eval; Eval for early intervention / special education Psychiatric/
Behavioral	Neuropsychiatric eval	For persons age 12 mos: screening for behavior concerns incl sleep disturbances, ADHD, anxiety, /or traits suggestive of ASD
Musculoskeletal	Orthopedics / physical medicine rehab / PT OT eval	To incl assessment of:; Gross motor fine motor skills; Contractures, clubfoot, kyphoscoliosis; Mobility, ADL, need for adaptive devices; Need for PT (to improve gross motor skills) /or OT (to improve fine motor skills) Gastrointestinal/
Feeding	Gastroenterology / nutrition / feeding team eval	To incl eval of aspiration risk nutritional status; Consider eval for gastric tube placement in persons w/dysphagia /or aspiration risk.
Eyes	Ophthalmologic eval	To assess for vision, abnormal ocular movement, best corrected visual acuity, refractive errors, strabismus; More complex findings may require subspecialty referral.
Hearing	Audiologic eval	To assess for hearing loss Genetic
counseling	By genetics professionals1	To inform affected persons their families re nature, MOI, implications of a KCNQ2-related disorder to facilitate medical personal decision making Family support resources
Treatment of Manifestations in Individuals with a KCNQ2-Related Disorder Manifestation/Concern	Treatment	Considerations/Other
Epilepsy	Standardized treatment w/ASM by experienced neurologist	Education of parents/caregivers1; Seizures in persons w/SLFNE are generally controlled w/conventional ASM treatment, while seizures in persons w/NEO-DEE may be resistant to multiple ASMs alone or in combination.
DD/ID	See .	Spasticity
dysfunction	Monitor for reflux or constipation.	Treatment as needed Ophthalmologic
involvement	By ophthalmologist	Treatment of refractive errors /or strabismus Central visual
impairment	No specific treatment	Early intervention program to stimulate visual development Hearing

Source: GeneReviews — "KCNQ2-Related Disorders"

Brand Name	Generic Name	Sponsor	Designated	Exclusivity End	Designation Status
topiramate	topiramate	PrevEP Inc.	2024	—	Designated
levetiracetam	levetiracetam	University of California	2010	—	Designated

Kisho

benign neonatal seizures

Overview

Clinical Presentation

Clinical Guidance

Diagnosis

Diagnostic Criteria

Suggestive Findings

Treatment

Approved Therapies

Prognosis

Surveillance Guidelines

Neurologic

Research Landscape

Medical References

External Resources

Orphanet

GARD

Questions for Your Care Team

Questions for Your Care Team

Differential Diagnosis

Orphan Drug Designations

Management Guidelines

Clinical Guidance

Therapies Under Investigation

Clinical Trials

Development

Behavioral

Musculoskeletal

Feeding

Gastrointestinal

Community

Recent Publications

benign neonatal seizures

Overview

Clinical Presentation

Clinical Guidance

Diagnosis

Diagnostic Criteria

Suggestive Findings

Treatment

Approved Therapies

Prognosis

Surveillance Guidelines

Neurologic

Research Landscape

Medical References

External Resources

Orphanet

GARD

Subtypes

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Differential Diagnosis

Orphan Drug Designations

Management Guidelines

Clinical Guidance

Therapies Under Investigation

Clinical Trials

Development

Behavioral

Musculoskeletal

Feeding

Gastrointestinal

Community

Recent Publications